此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Pharmacodynamics, Pharmacokinetics, and Safety of ASP1941 in Patients With Type 1 Diabetes Mellitus

2019年3月14日 更新者:Astellas Pharma Inc

A Phase 2, Clinical Pharmacological Study of ASP1941 in Japanese Patients With Type 1 Diabetes Mellitus

The objective of this study is to assess pharmacodynamics, pharmacokinetics, and safety of ASP1941 in patients with type 1 diabetes mellitus when administered once daily (q.d.) for 2 weeks.

研究概览

地位

完全的

研究类型

介入性

注册 (实际的)

43

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Aichi、日本
        • Site JP00006
      • Fukuoka、日本
        • Site JP00002
      • Gunma、日本
        • Site JP00009
      • Ibaraki、日本
        • Site JP00001
      • Kanagawa、日本
        • Site JP00008
      • Kanagawa、日本
        • Site JP00005
      • Okayama、日本
        • Site JP00003
      • Osaka、日本
        • Site JP00004
      • Osaka、日本
        • Site JP00010
      • Osaka、日本
        • Site JP00011
      • Tokyo、日本
        • Site JP00007

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

20年 至 74年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

At the time of obtaining informed consent:

  • Subject is diagnosed with type 1 diabetes mellitus and has been treated with insulin therapy for at least 52 weeks (364 days).
  • Subject is able to be admitted to the site as scheduled.
  • Subject is able to record in Patient's diary from the first study drug dose in observation period until the day before the end of post observation.

At screening period:

  • Subject has an HbA1c (NGSP) value of between 7.5% and 10.0%. If subject has an HbA1c value of between 7.3% and 10.2% (out of the reference range), HbA1c may be re-measured only once within the allowance range in screening period. Re-measured HbA1c (NGSP) value will be adopted for the determination.
  • Subject has been receiving insulin therapy at daily doses (instructed by a doctor) within a ±20% range for at least 12weeks (83days) prior to the start of screening.
  • Subject has a fasting serum C-peptide level ≤0.5 ng/mL at screening.
  • Subject receives treatments for complications (except for transient diseases such as a cold) that, in the investigator's or sub-investigator's opinion, need not to be changed during the period from the start of screening to the end of the treatment period.
  • Subject has body mass index (BMI) value of 20.0 to 35.0 kg/m2 at screening.

Exclusion Criteria:

At the time of obtaining informed consent:

  • Subject has type 2 diabetes mellitus.
  • Subject has participated or has been participating in a clinical study or a post marketing study of another drug or medical equipment within 12 weeks (84 days) prior to obtaining informed consent.
  • Subject has received ASP1941 (ipragliflozin) with the exception of placebo.

At screening period:

  • Subject has proliferative retinopathy (subjects with stable condition after photocoagulation etc. may be enrolled in the study).
  • Subject has developed hypoglycemia unawareness (requires help of a third person) or severe hypoglycemia (diabetic coma, precoma, or convulsion) within 12 weeks (84 days) prior to the start of screening.
  • Subject has developed diabetic ketoacidosis within 12 weeks (84 days) prior to the start of screening.
  • Subject has chronic disease(s) which require the continuous use of corticosteroids or immunosuppressants (oral administration, injection, inhalation, or suppository).
  • Subject has received hypoglycemic agent(s) other than insulin within 12 weeks (83 days) prior to the start of screening.
  • Subject with perioperative, severe infection or serious injury.
  • Subject whose serum creatinine value exceeds the upper limit of normal range at screening.
  • Subject has a urinary albumin/urinary creatinine ratio>300 mg/g in urinalysis at screening.
  • Subject has a history of clinically significant renal disease(s) such as renovascular occlusive disease, nephrectomy, and/or renal transplant.
  • Subject has AST and ALT >2 ×ULN or T-Bil >1.5 × ULN at screening, or has a history of serious hepatic diseases.
  • Subject presents with symptoms of dysuria, anuria, oliguria and urinary retention.
  • Subject has a history of recurrent urinary tract infections and recurrent genital infections (developed 3 times or more within 24 weeks (168 days) prior to the start of screening).
  • Subject has urinary tract infection or genital infection with subjective symptoms.
  • Subject has a history of angina unstable, myocardial infarction, angioplasty, and serious heart disease (NYHA Class II-IV) within 24 weeks (168 days) prior to the start of screening, or has complications of heart disease that, in the investigator's or sub-investigator's opinion, may interfere with the evaluation of safety of ASP1941.
  • Subject has uncontrolled blood pressure (systolic blood pressure≥160 mmHg or diastolic blood pressure≥100 mmHg in the supine position after a 5-minute rest at screening ).
  • Subject has serious gastrointestinal disease or a history of serious gastrointestinal operation.
  • Subject has malignant tumors concomitantly (subject may be enrolled in the study if the subject has a history of a malignant tumor which has not recurred without any treatment within 5 years prior to the start of screening).
  • Subject has psychiatric disorder that makes the subject unsuitable for study participation.
  • Subject has drug addiction or alcohol abuse.
  • Subject has a history of drug allergies.
  • Subject is unable to adhere to any of the compliance such as hospital visits and dose instruction specified in this study, or does not agree with it.
  • Subject has donated 400 mL of whole blood within 90 days, 200 mL of whole blood within 30 days, or blood components within 14 days prior to the start of screening.
  • Subject has any condition that, in the investigator's or sub-investigator's opinion, makes the subject unsuitable for study participation.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
安慰剂比较:安慰剂
每天一次
口服
实验性的:ASP1941 Low dose group
once daily
口服
其他名称:
  • 苏格拉特
  • 格列净
实验性的:ASP1941 Middle dose group
once daily
口服
其他名称:
  • 苏格拉特
  • 格列净
实验性的:ASP1941 High dose group
once daily
口服
其他名称:
  • 苏格拉特
  • 格列净

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Daily profile of plasma glucose levels
大体时间:up to Day 14
up to Day 14
Area under the concentration-time curve (AUC) 0-24hr (AUC0-24h) of plasma glucose levels
大体时间:at Day -1, Day 1 and Day 14
at Day -1, Day 1 and Day 14
AUC0-3h of plasma glucose levels
大体时间:at Day -1, Day 1 and Day 14
at Day -1, Day 1 and Day 14
AUC0-4h of plasma glucose levels
大体时间:up to Day 14
up to Day 14
AUC0-10h of plasma glucose levels
大体时间:up to Day 14
up to Day 14
Fasting plasma glucose levels
大体时间:up to Day 21
up to Day 21
Glycoalbumin
大体时间:up to Day 21
up to Day 21
Urinary glucose excretion
大体时间:up to Day 14
up to Day 14
Urinary glucose excretion rate
大体时间:up to Day 14
up to Day 14
Urine volume
大体时间:up to Day 14
up to Day 14
Urinary glucose concentration
大体时间:up to Day 15
up to Day 15
Body weight
大体时间:up to Day 21
up to Day 21
Renal glucose clearance
大体时间:up to Day 14
up to Day 14
Plasma concentration of unchanged ASP1941
大体时间:up to Day 14
up to Day 14
Urinary concentration of unchanged ASP1941
大体时间:up to Day 14
up to Day 14
Pharmacokinetics (PK) parameter of ASP1941 in plasma: AUC from time 0 extrapolated to infinity (AUCinf)
大体时间:at Day 1
at Day 1
PK parameter of ASP1941 in plasma: AUC from the time of dosing to the last measurable concentration (AUClast)
大体时间:at Day 1 and Day 14
at Day 1 and Day 14
PK parameter of ASP1941 in plasma: AUC from the time of dosing to 24 hr (AUC0-24h)
大体时间:at Day 1 and Day 14
at Day 1 and Day 14
PK parameter of ASP1941 in plasma: Oral Clearance (CL/F)
大体时间:at Day 1 and Day 14
at Day 1 and Day 14
PK parameter of ASP1941 in plasma: Maximum concentration (Cmax)
大体时间:at Day 1 and Day 14
at Day 1 and Day 14
PK parameter of ASP1941 in plasma: Terminal Elimination Half-life (t1/2)
大体时间:at Day 1 and Day 14
at Day 1 and Day 14
PK parameter of ASP1941 in plasma: Time of the Maximum Concentration (tmax)
大体时间:at Day 1 and Day 14
at Day 1 and Day 14
PK parameter of ASP1941 in urine: Amount excreted in urine between time (Ae)
大体时间:at Day 1 and Day 14
at Day 1 and Day 14
PK parameter of ASP1941 in urine: % of the dose of excreted in urine (Ae%)
大体时间:at Day 1 and Day 14
at Day 1 and Day 14
PK parameter of ASP1941 in plasma and urine: Renal Clearance (CLr)
大体时间:at Day 1 and Day 14
at Day 1 and Day 14
Safety assessed by vital signs
大体时间:up to Day 21
Supine blood pressure and supine pulse rate
up to Day 21
Safety assessed by 12-lead electrocardiogram
大体时间:up to Day 21
up to Day 21
Safety assessed by laboratory tests
大体时间:up to Day 21
Hematology, biochemistry and urinalysis
up to Day 21
Safety assessed by self-monitored blood glucose levels
大体时间:up to Day 21
up to Day 21
Safety assessed by Adverse events
大体时间:up to Day 21
up to Day 21

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2015年9月1日

初级完成 (实际的)

2016年3月19日

研究完成 (实际的)

2016年3月19日

研究注册日期

首次提交

2015年8月18日

首先提交符合 QC 标准的

2015年8月19日

首次发布 (估计)

2015年8月20日

研究记录更新

最后更新发布 (实际的)

2019年3月18日

上次提交的符合 QC 标准的更新

2019年3月14日

最后验证

2019年3月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under "Sponsor Specific Details for Astellas."

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅